ACHE and early-onset autosomal dominant Alzheimer disease: Furthermore, several other AChEIs are presently undergoingclinical trials for potential inclusion in future advancements inthe field of Alzheimer’s disease treatment.17 In addition to the potency against AChE, the developmentof selective AChE inhibitors has always been one of the focuses forthe development of novel treatments against Alzheimer’s disease,since the inhibition of butyrylcholinesterase (BuChE) can result inseveral adverse effects.